neostigmine has been researched along with Anaphylaxis in 17 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
Anaphylaxis: An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.
Excerpt | Relevance | Reference |
---|---|---|
"This was a retrospective multicentre observational study of patients who underwent surgery under general anaesthesia between 2012 and 2016 to compare the incidence of anaphylaxis with sugammadex with that of neostigmine at four tertiary hospitals in Japan." | 7.96 | Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study. ( Horiuchi, T; Nagumo, K; Orihara, M; Saito, S; Sakamoto, S; Takazawa, T; Tomioka, A; Tomita, Y; Yokohama, A; Yoshida, N, 2020) |
"A patient developed anaphylaxis during anaesthesia, towards the end of surgery, 30 s after intravenous administration of neostigmine." | 7.70 | Anaphylaxis caused by neostigmine. ( Ewan, PW; Seed, MJ, 2000) |
" Participants aged 2 to <17 years, under moderate or deep neuromuscular blockade, were administered sugammadex (2 or 4 mg/kg) or neostigmine (50 µg/kg; for moderate neuromuscular blockade only)." | 5.51 | Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study. ( DeAngelis, M; Hammer, GB; Herring, WJ; Saldien, V; Speek, M; Voss, T; Wang, A; Wrishko, R, 2022) |
"Sugammadex and neostigmine given to reverse residual neuromuscular blockade can cause side effects including bradycardia, anaphylaxis, bronchospasm, and even cardiac arrest." | 4.12 | Sugammadex Versus Neostigmine for Reversal of Residual Neuromuscular Blocks After Surgery: A Retrospective Cohort Analysis of Postoperative Side Effects. ( Chahar, P; Chhabada, S; Khanna, S; Li, K; Maheshwari, K; Ruetzler, K; Schmidt, MT; Sessler, DI; Turan, A; Yang, D, 2022) |
"This was a retrospective multicentre observational study of patients who underwent surgery under general anaesthesia between 2012 and 2016 to compare the incidence of anaphylaxis with sugammadex with that of neostigmine at four tertiary hospitals in Japan." | 3.96 | Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study. ( Horiuchi, T; Nagumo, K; Orihara, M; Saito, S; Sakamoto, S; Takazawa, T; Tomioka, A; Tomita, Y; Yokohama, A; Yoshida, N, 2020) |
" The automated MedDRA query method showed no apparent increase in hypersensitivity or anaphylaxis with sugammadex as compared to placebo or neostigmine." | 3.88 | Incidence of hypersensitivity and anaphylaxis with sugammadex. ( Adkinson, F; Assaid, C; Gurner, DM; Herring, WJ; McCrea, J; Min, KC; Sisk, CM; Woo, T, 2018) |
" Immunized BP2 mice developed an acute bronchoconstriction in vivo and airway muscle contraction in vitro in response to ovalbumin (OA) and these contractions were dose dependent." | 3.70 | Anaphylactic bronchoconstriction in BP2 mice: interactions between serotonin and acetylcholine. ( Brink, C; Eum, SY; Labat, C; Lefort, J; Norel, X; Vargaftig, BB, 1999) |
"A patient developed anaphylaxis during anaesthesia, towards the end of surgery, 30 s after intravenous administration of neostigmine." | 3.70 | Anaphylaxis caused by neostigmine. ( Ewan, PW; Seed, MJ, 2000) |
"Anaphylactoid reaction is a rapid systemic allergic reaction to many kinds of allergen." | 1.43 | [Anaphylactoid Reactions Suspected to Be Caused by Neostigmine in Pediatric Patients under General Anesthesia]. ( Arai, M; Asagoe, Y; Iwasai, S; Kinoshita, Y; Matsuzaki, T; Sato, T, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (17.65) | 18.7374 |
1990's | 1 (5.88) | 18.2507 |
2000's | 4 (23.53) | 29.6817 |
2010's | 3 (17.65) | 24.3611 |
2020's | 6 (35.29) | 2.80 |
Authors | Studies |
---|---|
Voss, T | 1 |
Wang, A | 1 |
DeAngelis, M | 1 |
Speek, M | 1 |
Saldien, V | 1 |
Hammer, GB | 1 |
Wrishko, R | 1 |
Herring, WJ | 2 |
Ruetzler, K | 1 |
Li, K | 1 |
Chhabada, S | 1 |
Maheshwari, K | 1 |
Chahar, P | 1 |
Khanna, S | 1 |
Schmidt, MT | 1 |
Yang, D | 1 |
Turan, A | 1 |
Sessler, DI | 1 |
Orihara, M | 1 |
Takazawa, T | 1 |
Horiuchi, T | 1 |
Sakamoto, S | 1 |
Nagumo, K | 1 |
Tomita, Y | 1 |
Tomioka, A | 1 |
Yoshida, N | 1 |
Yokohama, A | 1 |
Saito, S | 1 |
McKenzie, AJ | 1 |
Banik, RK | 1 |
Karuppiah, S | 1 |
Kaizer, AM | 1 |
de Boer, HD | 1 |
Hunter, JM | 1 |
Min, KC | 1 |
Woo, T | 1 |
Assaid, C | 1 |
McCrea, J | 1 |
Gurner, DM | 1 |
Sisk, CM | 1 |
Adkinson, F | 1 |
Hermite, L | 1 |
Louvier, N | 1 |
Hilaire, P | 1 |
Orry, D | 1 |
Seltzer, S | 1 |
Collet, E | 1 |
Iwasai, S | 1 |
Kinoshita, Y | 1 |
Asagoe, Y | 1 |
Matsuzaki, T | 1 |
Arai, M | 1 |
Sato, T | 1 |
RITTWAGEN, M | 1 |
ROMANO, FJ | 1 |
SVIGALS, MP | 1 |
Coelho, D | 1 |
Fernandes, T | 1 |
Branga, P | 1 |
Malheiro, D | 1 |
Rodrigues, J | 1 |
Nezhinskaya, GI | 1 |
Vladykin, AL | 1 |
Sapronov, NS | 1 |
Eum, SY | 1 |
Norel, X | 1 |
Lefort, J | 1 |
Labat, C | 1 |
Vargaftig, BB | 1 |
Brink, C | 1 |
Seed, MJ | 1 |
Ewan, PW | 1 |
McNicholas, JJ | 1 |
Harban, FM | 1 |
Lysenkov, SP | 1 |
Proskuriakov, IA | 1 |
Rosenthale, ME | 1 |
Dervinis, A | 1 |
Kassarich, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants[NCT03351608] | Phase 4 | 288 participants (Actual) | Interventional | 2018-02-12 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Vz of sugammadex, defined as the amount of drug administered relative to plasma concentrations, was determined in each Part A arm. (NCT03351608)
Timeframe: 2 minutes (min), 15 min, 30 min, 60 min, 4-6 hours (hrs), and 10 hrs post-dose
Intervention | Liters (Geometric Mean) |
---|---|
Part A: Sugammadex 2 mg (2 to <6 Years) | 3.58 |
Part A: Sugammadex 2 mg (6 to <12 Years) | 6.65 |
Part A: Sugammadex 2 mg (12 to <17 Years) | 10.8 |
Part A: Sugammadex 4 mg (2 to <6 Years) | 4.00 |
Part A: Sugammadex 4 mg (6 to <12 Years) | 8.22 |
Part A: Sugammadex 4 mg (12 to <17 Years) | 12.3 |
The AUCo-∞ for sugammadex, defined as the area under the plasma concentration versus time plot, was determined in each Part A arm. (NCT03351608)
Timeframe: 2 minutes (min), 15 min, 30 min, 60 min, 4-6 hours (hrs), and 10 hrs post-dose
Intervention | hr*μg/mL (Geometric Mean) |
---|---|
Part A: Sugammadex 2 mg (2 to <6 Years) | 14.1 |
Part A: Sugammadex 2 mg (6 to <12 Years) | 18.8 |
Part A: Sugammadex 2 mg (12 to <17 Years) | 27.6 |
Part A: Sugammadex 4 mg (2 to <6 Years) | 26.9 |
Part A: Sugammadex 4 mg (6 to <12 Years) | 38.2 |
Part A: Sugammadex 4 mg (12 to <17 Years) | 49.2 |
The Cmax of sugammadex, defined as the maximum plasma concentration, was determined in each Part A arm. (NCT03351608)
Timeframe: 2 minutes (min), 15 min, 30 min, 60 min, 4-6 hours (hrs), and 10 hrs post-dose
Intervention | µg/mL (Geometric Mean) |
---|---|
Part A: Sugammadex 2 mg (2 to <6 Years) | 17.5 |
Part A: Sugammadex 2 mg (6 to <12 Years) | 32.2 |
Part A: Sugammadex 2 mg (12 to <17 Years) | 41.3 |
Part A: Sugammadex 4 mg (2 to <6 Years) | 47.1 |
Part A: Sugammadex 4 mg (6 to <12 Years) | 51.6 |
Part A: Sugammadex 4 mg (12 to <17 Years) | 61.9 |
The percentage of participants with ≥1 AE(s) for up to 7 days after treatment was determined for each treatment group, pooled according to treatment received. An AE is defined as any unfavorable and unintended medical occurrence, symptom, or disease witnessed in a participant, regardless of whether or not a causal relationship with the study treatment can be demonstrated. (NCT03351608)
Timeframe: Up to 7 days
Intervention | Percentage of Participants (Number) |
---|---|
Part B: Neostigmine + (Glycopyrrolate or Atropine) | 97.1 |
Parts A and B: Sugammadex 2 mg | 78.4 |
Parts A and B: Sugammadex 4 mg | 74.9 |
The CL of sugammadex, defined as the rate of elimination relative to plasma concentration, was determined in each Part A arm. (NCT03351608)
Timeframe: 2 minutes (min), 15 min, 30 min, 60 min, 4-6 hours (hrs), and 10 hrs post-dose
Intervention | L/hr (Geometric Mean) |
---|---|
Part A: Sugammadex 2 mg (2 to <6 Years) | 2.30 |
Part A: Sugammadex 2 mg (6 to <12 Years) | 3.58 |
Part A: Sugammadex 2 mg (12 to <17 Years) | 4.68 |
Part A: Sugammadex 4 mg (2 to <6 Years) | 2.26 |
Part A: Sugammadex 4 mg (6 to <12 Years) | 3.43 |
Part A: Sugammadex 4 mg (12 to <17 Years) | 5.69 |
The t½ of sugammadex, defined as the time required for the plasma concentration to decrease to 50% of maximum, was determined in each Part A arm. (NCT03351608)
Timeframe: 2 minutes (min), 15 min, 30 min, 60 min, 4-6 hours (hrs), and 10 hrs post-dose
Intervention | Hours (Median) |
---|---|
Part A: Sugammadex 2 mg (2 to <6 Years) | 1.15 |
Part A: Sugammadex 2 mg (6 to <12 Years) | 1.19 |
Part A: Sugammadex 2 mg (12 to <17 Years) | 1.49 |
Part A: Sugammadex 4 mg (2 to <6 Years) | 1.12 |
Part A: Sugammadex 4 mg (6 to <12 Years) | 1.56 |
Part A: Sugammadex 4 mg (12 to <17 Years) | 1.51 |
The time to recovery of TOF ratio to ≥0.7 after administration of study intervention was determined for each Part B arm. The TOF ratio is the ratio of the magnitude of the fourth (T4) and first (T1) thumb twitches elicited by 4 electrical stimulations of the ulnar nerve, indicating the current degree of NMB as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Values closer to 1 indicate less NMB. (NCT03351608)
Timeframe: Up to 30 minutes post-dose
Intervention | Minutes (Geometric Mean) |
---|---|
Part B: Sugammadex 2 mg/kg | 1.1 |
Part B: Sugammadex 4 mg/kg | 1.3 |
Part B: Neostigmine + (Glycopyrrolate or Atropine) | 3.7 |
The time to recovery of TOF ratio to ≥0.8 after administration of study intervention was determined for each Part B arm. The TOF ratio is the ratio of the magnitude of the fourth (T4) and first (T1) thumb twitches elicited by 4 electrical stimulations of the ulnar nerve, indicating the current degree of NMB as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Values closer to 1 indicate less NMB. (NCT03351608)
Timeframe: Up to 30 minutes post-dose
Intervention | Minutes (Geometric Mean) |
---|---|
Part B: Sugammadex 2 mg/kg | 1.3 |
Part B: Sugammadex 4 mg/kg | 1.5 |
Part B: Neostigmine + (Glycopyrrolate or Atropine) | 5.0 |
The time to recovery of TOF ratio to ≥0.9 after administration of study intervention was determined for each Part B arm. The TOF ratio is the ratio of the magnitude of the fourth (T4) and first (T1) thumb twitches elicited by 4 electrical stimulations of the ulnar nerve, indicating the current degree of NMB as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Values closer to 1 indicate less NMB. Per protocol, the efficacy analysis is based on comparison of the Part B: Sugammadex 2 mg arm versus the Part B: Neostigmine + (Glycopyrrolate or Atropine) arm. (NCT03351608)
Timeframe: Up to 30 minutes post-dose
Intervention | Minutes (Geometric Mean) |
---|---|
Part B: Sugammadex 2 mg/kg | 1.6 |
Part B: Sugammadex 4 mg/kg | 1.9 |
Part B: Neostigmine + (Glycopyrrolate or Atropine) | 7.5 |
1 trial available for neostigmine and Anaphylaxis
Article | Year |
---|---|
Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study.
Topics: Anaphylaxis; Anesthetics; Bradycardia; Child; Humans; Neostigmine; Neuromuscular Blockade; Neuromusc | 2022 |
16 other studies available for neostigmine and Anaphylaxis
Article | Year |
---|---|
Sugammadex Versus Neostigmine for Reversal of Residual Neuromuscular Blocks After Surgery: A Retrospective Cohort Analysis of Postoperative Side Effects.
Topics: Anaphylaxis; Bradycardia; Bronchial Spasm; Child; Cohort Studies; Delayed Emergence from Anesthesia; | 2022 |
Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study.
Topics: Adolescent; Adult; Aged; Anaphylaxis; Cholinesterase Inhibitors; Female; Humans; Incidence; Japan; M | 2020 |
Neostigmine anaphlaxis: A rare and missed diagnosis.
Topics: Anaphylaxis; Cholinesterase Inhibitors; Humans; Missed Diagnosis; Neostigmine | 2020 |
Statistical significance versus clinical relevance. Comment on Br J Anaesth 2020; 124: 154-63.
Topics: Anaphylaxis; Humans; Incidence; Neostigmine; Retrospective Studies; Sugammadex | 2020 |
Sugammadex or neostigmine: should potential anaphylaxis be the overriding factor in the choice of a reversal drug? Comment on Br J Anaesth 2020; 124: 154-63.
Topics: Anaphylaxis; Humans; Incidence; Neostigmine; Neuromuscular Blockade; Retrospective Studies; Sugammad | 2020 |
Incidence of hypersensitivity and anaphylaxis with sugammadex.
Topics: Adult; Aged; Anaphylaxis; Anesthesia Recovery Period; Anesthesia, General; Cholinesterase Inhibitors | 2018 |
Neostigmine induced anaphylaxis in the wake of surgery.
Topics: Aged; Anaphylaxis; Cholinesterase Inhibitors; Female; Humans; Neostigmine; Postoperative Complicatio | 2015 |
[Anaphylactoid Reactions Suspected to Be Caused by Neostigmine in Pediatric Patients under General Anesthesia].
Topics: Anaphylaxis; Anesthesia, General; Female; Humans; Infant; Male; Neostigmine | 2016 |
A study on the incidence of allergy in children with rheumatic fever.
Topics: Anaphylaxis; Child; Hypersensitivity; Immune System Diseases; Incidence; Infant; Neostigmine; Rheuma | 1946 |
Intraoperative anaphylaxis after intravenous atropine.
Topics: Adjuvants, Anesthesia; Aged; Anaphylaxis; Anesthesia, General; Anti-Inflammatory Agents; Atropine; B | 2007 |
Cholinergic modulation of anaphylactic shock: plasma proteins influence.
Topics: Anaphylaxis; Animals; Blood Proteins; C-Reactive Protein; Cholinergic Agents; Cholinesterase Inhibit | 2007 |
Anaphylactic bronchoconstriction in BP2 mice: interactions between serotonin and acetylcholine.
Topics: Acetylcholine; Anaphylaxis; Animals; Atropine; Bronchoconstriction; Bronchodilator Agents; Cholinest | 1999 |
Anaphylaxis caused by neostigmine.
Topics: Anaphylaxis; Cholinesterase Inhibitors; Female; Humans; Intraoperative Complications; Middle Aged; N | 2000 |
Anaphylaxis caused by neostigmine.
Topics: Anaphylaxis; Cholinesterase Inhibitors; Edrophonium; Humans; Neostigmine; Neuromuscular Blockade | 2000 |
[Allergic shock caused by trimecaine in prolonged peridural blockade].
Topics: Acetanilides; Adolescent; Anaphylaxis; Anesthesia, Epidural; Female; Humans; Neostigmine; Time Facto | 1978 |
Bronchodilator activity of the prostaglandins E 1 and E 2 .
Topics: Aerosols; Airway Resistance; Anaphylaxis; Animals; Blood Pressure; Bronchodilator Agents; Cats; Cycl | 1971 |